[go: up one dir, main page]

NO20053965L - Fremgangsmate for fremstilling av belagt preparat - Google Patents

Fremgangsmate for fremstilling av belagt preparat

Info

Publication number
NO20053965L
NO20053965L NO20053965A NO20053965A NO20053965L NO 20053965 L NO20053965 L NO 20053965L NO 20053965 A NO20053965 A NO 20053965A NO 20053965 A NO20053965 A NO 20053965A NO 20053965 L NO20053965 L NO 20053965L
Authority
NO
Norway
Prior art keywords
preparation
coated
pioglitazone hydrochloride
remedy
useful
Prior art date
Application number
NO20053965A
Other languages
English (en)
Inventor
Hiroyoshi Koyama
Naoru Hamaguchi
Kazuhiro Ohkouchi
Masahiko Koike
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32830627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053965(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20053965L publication Critical patent/NO20053965L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er tilveiebrakt en fremgangsmåte for fremstilling av et preparat belagt med pioglitazonhydroklorid som er anvendelig som et remedie middel for diabetes etc. og har svært gode fremstillingskarakteristikker slik som elueringsegenskaper av pioglitazonhydroklorid.
NO20053965A 2003-01-29 2005-08-25 Fremgangsmate for fremstilling av belagt preparat NO20053965L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003020925 2003-01-29
JP2003276894 2003-07-18
JP2004001128 2004-01-06
PCT/JP2004/000754 WO2004067001A1 (ja) 2003-01-29 2004-01-28 被覆製剤の製造法

Publications (1)

Publication Number Publication Date
NO20053965L true NO20053965L (no) 2005-08-25

Family

ID=32830627

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053965A NO20053965L (no) 2003-01-29 2005-08-25 Fremgangsmate for fremstilling av belagt preparat

Country Status (14)

Country Link
US (1) US7976853B2 (no)
EP (1) EP1588708A4 (no)
KR (1) KR101114808B1 (no)
AU (1) AU2004208606B2 (no)
BR (1) BRPI0407074A (no)
CA (1) CA2514539C (no)
CR (1) CR7929A (no)
IL (1) IL169870A (no)
MA (1) MA27624A1 (no)
MX (1) MXPA05007883A (no)
NO (1) NO20053965L (no)
NZ (1) NZ541749A (no)
PL (1) PL377403A1 (no)
WO (1) WO2004067001A1 (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
NZ546337A (en) 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
CA2562391A1 (en) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
TWI274889B (en) * 2005-10-06 2007-03-01 Elan Microelectronics Corp Resistive touch screen measurement system
NZ569071A (en) * 2005-12-22 2011-01-28 Takeda Pharmaceutical Solid preparation containing an insulin sensitizer
KR101464007B1 (ko) * 2006-08-10 2014-11-20 다케다 야쿠힌 고교 가부시키가이샤 약학 조성물
CA2677201C (en) * 2007-02-01 2015-11-17 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and pioglitazone
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
MX2010001335A (es) 2007-07-31 2010-06-02 Lifescan Inc Diferenciacion de celulas madre embrionarias humanas.
ES2372463T3 (es) 2007-11-27 2012-01-20 Lifescan, Inc. Diferenciación de células madre embrionarias humanas.
CN102046779A (zh) 2008-02-21 2011-05-04 森托科尔奥索生物科技公司 用于细胞粘附、培养和分离的方法、表面改性培养板和组合物
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
EP2190417A2 (en) * 2008-03-26 2010-06-02 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
JP5734183B2 (ja) 2008-06-30 2015-06-17 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞の分化
CN102272291B (zh) 2008-10-31 2018-01-16 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
AU2009316580B2 (en) 2008-11-20 2016-04-14 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
MX2011005289A (es) 2008-11-20 2011-06-01 Centocor Ortho Biotech Inc Metodos y composiciones para union y cultivo celular sobre sustratos planares.
JP6219568B2 (ja) 2009-07-20 2017-10-25 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の分化
RU2701335C2 (ru) 2009-12-23 2019-09-25 Янссен Байотек, Инк. Способ получения популяции панкреатических эндокринных клеток, соэкспрессирующих nkx6.1 и инсулин, и способ лечения диабета
BR112012022145A2 (pt) 2010-03-01 2020-10-06 Janssen Biotech, Inc. métodos para purificar células derivadas de células-tronco pluripotentes
KR101986176B1 (ko) 2010-05-12 2019-06-05 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
CN103221536B (zh) 2010-08-31 2016-08-31 詹森生物科技公司 人胚胎干细胞的分化
EP2611910B1 (en) 2010-08-31 2018-01-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
EP2611434A1 (en) 2010-09-01 2013-07-10 Lupin Limited Pharmaceutical composition comprising metformin and pioglitazone
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
CA2860107C (en) 2011-12-22 2021-06-01 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
HK1206058A1 (en) 2012-03-07 2015-12-31 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
ES2897649T3 (es) 2012-06-08 2022-03-02 Janssen Biotech Inc Diferenciación de células madre embrionarias humanas en células endocrinas pancreáticas
EP2674149B1 (en) * 2012-06-15 2017-10-04 Shin-Etsu Chemical Co., Ltd. Method of preparing composite granule comprising low-substituted hydroxypropyl cellulose and rapid release preparation
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
EP2938724B1 (en) 2012-12-31 2020-10-28 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
HK1217727A1 (zh) 2012-12-31 2017-01-20 Janssen Biotech, Inc. 用於分化成胰腺內分泌細胞的人多能細胞的懸浮和群集
EP4219683A1 (en) 2012-12-31 2023-08-02 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
HRP20190360T1 (hr) * 2013-06-17 2019-04-05 Nippon Soda Co., Ltd. Obložno sredstvo koje sadrži hidroksialkilcelulozu
KR101597004B1 (ko) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
DK3143127T3 (da) 2014-05-16 2021-09-13 Janssen Biotech Inc Anvendelse af små molekyler til at forstærke mafa-ekspression i endokrine pankreasceller
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
RU2690677C1 (ru) * 2018-06-27 2019-06-05 Георгий Георгиевич Чумбуридзе Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью
CN112461947B (zh) * 2020-10-27 2022-06-28 山东省药学科学院 一种盐酸吡格列酮片溶出曲线的测定方法
CN120392688B (zh) * 2025-07-02 2025-09-16 浙江大学 一种盐酸吡格列酮和二甲双胍复方片剂及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5179716A (en) * 1974-12-28 1976-07-12 Shinetsu Chemical Co Kokeiiyakuseizaino seizohoho
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
ES2124794T3 (es) * 1992-10-09 1999-02-16 Kanegafuchi Chemical Ind Procedimiento para producir granulados finos.
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
HU228260B1 (en) 1993-09-15 2013-02-28 Daiichi Sankyo Company Pharmaceutical compositions to treat impaired glucose tolerance
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
CN1114404C (zh) 1997-06-18 2003-07-16 史密丝克莱恩比彻姆有限公司 用噻唑烷二酮和二甲双胍治疗糖尿病
US20020004515A1 (en) 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
BR9908911A (pt) 1998-03-19 2001-10-02 Bristol Myers Squibb Co Sistema bifásico e processo de distribuição por liberação controlada de substâncias farmacêuticas de alta solubilidade
WO2000016776A1 (fr) * 1998-09-18 2000-03-30 Takeda Chemical Industries, Ltd. Preparations a administrer par voie buccale a liberation lente
WO2000024423A1 (en) * 1998-10-26 2000-05-04 Tanabe Seiyaku Co., Ltd. Sustained-release particles
AR023700A1 (es) 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
WO2000028989A1 (en) 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6168806B1 (en) * 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
AU1403501A (en) * 1999-11-16 2001-05-30 Smithkline Beecham Plc Novel composition and use
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
CA2399463A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Combination drug
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6403121B1 (en) * 2000-05-01 2002-06-11 Aeropharm Technology Incorporated Core formulation
US6780432B1 (en) 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
JP2001342185A (ja) * 2000-06-02 2001-12-11 Nichiko Pharmaceutical Co Ltd フィルムコーティングされた塩酸ラニチジン錠剤
EP1738751B1 (en) 2001-01-12 2011-05-11 Sun Pharma Advanced Research Company Ltd Spaced drug delivery system
EP1364650A1 (en) * 2001-01-30 2003-11-26 Teijin Limited Medicinal composition
EP1429747A4 (en) 2001-07-10 2005-01-05 Kos Life Sciences Inc CORE FORMULATION WITH PIOGLITAZONE HYDROCHLORIDE AND A BIGUANIDE
US20030187074A1 (en) 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
AU2003281181A1 (en) 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
JP4694841B2 (ja) 2002-09-20 2011-06-08 アンドルックス ラボズ リミテッド ライアビリティ カンパニー ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
IN192749B (no) * 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
WO2004069229A1 (en) 2003-02-05 2004-08-19 Ipca Laboratories Limited Dual release anti-diabetic drugs and process of production thereof

Also Published As

Publication number Publication date
AU2004208606B2 (en) 2009-09-24
CA2514539A1 (en) 2004-08-12
PL377403A1 (pl) 2006-02-06
KR101114808B1 (ko) 2012-02-15
AU2004208606A1 (en) 2004-08-12
MXPA05007883A (es) 2005-09-21
IL169870A (en) 2012-07-31
NZ541749A (en) 2009-06-26
EP1588708A4 (en) 2006-03-01
MA27624A1 (fr) 2005-11-01
EP1588708A1 (en) 2005-10-26
CR7929A (es) 2005-11-28
KR20050096958A (ko) 2005-10-06
US7976853B2 (en) 2011-07-12
US20060141128A1 (en) 2006-06-29
CA2514539C (en) 2012-03-06
BRPI0407074A (pt) 2006-01-24
WO2004067001A1 (ja) 2004-08-12

Similar Documents

Publication Publication Date Title
NO20053965L (no) Fremgangsmate for fremstilling av belagt preparat
AU2022402959A1 (en) Dual-targeting compound, and preparation method therefor and use thereof
NO20092692L (no) MAPK/ERK kinaseinhibitorer
EP4015520A4 (en) OXYGEN-CONTAINING HETEROCYCLIC COMPOUND, PROCESS FOR THEIR PRODUCTION AND ITS USE
ATE485849T1 (de) Polymerzusammensetzungen, überzüge und vorrichtungen und herstellungs- und anwendungsverfahren damit
CY2014042I1 (el) Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζολιου, φαρμακα που περιεχουν τις ενωσεις αυτες, χρηση αυτων και μεθοδος για την παραγωγη τους
NO20063620L (no) Arylanilinderivater som beta2 adrenergiske receptoragonister
NO20082278L (no) Triazolderivater som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase-1
NO20070176L (no) Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav
NO20080789L (no) 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
EP1797034A4 (en) SULFONYL COMPOUNDS AS AN INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE-1
MX2010004319A (es) Compuesto de alfa-(n-sulfonamido)acetamida novedoso como un inhibidor de producccion de peptido beta amiloide.
GEP20084367B (en) Diazepinoindole derivatives as kinase inhibitors
NO20066055L (no) Pyridinderivater
EP2702988A3 (en) Novel compositions and methods for treating hyperproliferative diseases
NO20082112L (no) 3-Amino-2-arylpropylazaindoler og deres anvendelse
WO2009022328A3 (en) Regulators of mmp-9 and uses therof
EP4186905A4 (en) COMPOUND AS BTK INHIBITOR, METHOD OF PREPARING IT AND USE THEREOF
EP3991857A4 (en) Primary anticorrosion coating composition, substrate with primary anticorrosion coating membrane, and manufacturing method therefor
NO20070565L (no) Kinolin tiazolinoner med CDK1 antiproliferativ aktivitet
EP4238958A4 (en) 2-CYANOACRYLATE COMPOUND, METHOD FOR PREPARING IT AND ITS USE
NO20070564L (no) Kinoliner uten tiazolinonsubstituenter.
NO20080175L (no) Sukkerbelagt tablett
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
DK1994005T3 (da) Tetrahydronaphthalinderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelseshæmmere

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application